Monica Golumbeanu

Monica Golumbeanu

Auto-generated profile, based on publicly available information

Monica Golumbeanu

Swiss Tropical and Public Health Institute, Allschwil, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cell Reports
Verified
Journal Article
Open access
MGMonica Golumbeanu
Monica Golumbeanu
SCSara Cristinelli
Sara Cristinelli
SRSylvie Rato
Sylvie Rato
MMMiguel Munoz
Miguel Munoz
MCMatthias Cavassini
Matthias Cavassini
Angela CiuffiAngela Ciuffi
Angela Ciuffi
Despite effective treatment, HIV can persist in latent reservoirs, which represent a major obstacle toward HIV eradication. Targeting and reactivating latent cells is challenging due to the heterogeneous nature of HIV-infected cells. Here, we used a primary model of HIV latency and single-cell RNA sequencing to characterize transcriptional heterogeneity during HIV latency and reactivation. Our analysis identified transcriptional programs leading to successful reactivation of HIV expression.

3 March 2015 in RNA
Verified
Journal Article
Open access
PDF file
NINicolas Innocenti
Nicolas Innocenti
MGMonica Golumbeanu
Monica Golumbeanu
ADAymeric Fouquier D'HÉrouël
Aymeric Fouquier D'HÉrouël
CLCaroline Lacoux
Caroline Lacoux
Rémy BonninRémy Bonnin
Rémy Bonnin
EAErik Aurell
Erik Aurell
Enterococcus faecalis is the third cause of nosocomial infections. To obtain the first snapshot of transcriptional organizations in this bacterium, we used a modified RNA-seq approach enabling to discriminate primary from processed 5′ RNA ends. We also validated our approach by confirming known features in Escherichia coli. We mapped 559 transcription start sites (TSSs) and 352 processing sites (PSSs) in E. faecalis. A blind motif search retrieved canonical features of SigA- and SigN-dependent promoters preceding transcription start sites mapped. We discovered 85 novel putative regulatory RNAs, small- and antisense RNAs, and 72 transcriptional antisense organizations. Presented data constitute a significant insight into bacterial RNA landscapes and a step toward the inference of regulatory processes at transcriptional and post-transcriptional levels in a comprehensive manner.

18 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMonica Golumbeanu
Monica Golumbeanu
SDSébastien Desfarges
Sébastien Desfarges
CHCéline Hernandez
Céline Hernandez
MQManfredo R. Quadroni
Manfredo R. Quadroni
SRSylvie Rato
Sylvie Rato
Angela CiuffiAngela Ciuffi
Angela Ciuffi
Throughout the HIV-1 replication cycle, complex host-pathogen interactions take place in the infected cell, leading to the production of new virions. The virus modulates the host cellular machinery in order to support its life cycle, while counteracting intracellular defense mechanisms. We investigated the dynamic host response to HIV-1 infection by systematically measuring transcriptomic, proteomic, and phosphoproteomic expression changes in infected and uninfected SupT1 CD4+ T cells at five time points of the viral replication process. By means of a Gaussian mixed-effects model implemented in the new R/Bioconductor package TMixClust, we clustered host genes based on their temporal expression patterns. We identified a proteo-transcriptomic gene expression signature of 388 host genes specific for HIV-1 replication. Comprehensive functional analyses of these genes confirmed the previously described roles of some of the genes and revealed novel key virus-host interactions affecting multiple molecular processes within the host cell, including signal transduction, metabolism, cell cycle, and immune system. The results of our analysis are accessible through a freely available, dedicated and user-friendly R/Shiny application, called PEACHi2.0. This resource constitutes a catalogue of dynamic host responses to HIV-1 infection that provides a basis for a more comprehensive understanding of virus-host interactions.

7 January 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
MGMonica Golumbeanu
Monica Golumbeanu
CEConstant A. V. Edi
Constant A. V. Edi
MHManuel Hetzel
Manuel Hetzel
CKCristian Koepfli
Cristian Koepfli
CNChristian Nsanzabana
Christian Nsanzabana
: An increasing number of molecular and genomic assays are available to study malaria parasite populations. However, so far they have played a marginal role in informing policy and programmatic decision-making. Currently, molecular data are mainly used for monitoring drug efficacy against Plasmodium falciparum; assessing molecular markers of drug and insecticide resistance; and assessing P. falciparum histidine-rich protein 2 and 3 genes (Pfhrp2/3) deletion. We argue that additional use cases for molecular routine surveillance could be implemented in the near future, especially in transmission settings approaching elimination. These would include using quantitative polymerase chain reaction to monitor the prevalence of sub-patent infections in asymptomatic carriers, monitoring parasite genetic diversity as transmission intensity is changing, using genomic data to determine the origin of imported infections and characterize transmission chains in settings with very low malaria transmission, and using serology to monitor recent and past exposures in low-transmission settings. Molecular surveillance could inform control programs on adapting novel strategies, such as reactive case detection or focal mass drug administration, and help evaluate the impact of interventions currently in place. To better integrate molecular and genomic data into control program decision-making, engagement of national malaria control experts is crucial. Local laboratory capacity needs to be strengthened, shortening the time from sample collection to data availability. Here, we discuss opportunities and challenges of the use of molecular and genomic data for supporting malaria control and elimination efforts, as well as the avenues to link molecular and genomic data with gold standard epidemiological measurements through mathematical modeling.

14 March 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
LBLydia Burgert
Lydia Burgert
TRTheresa Reiker
Theresa Reiker
MGMonica Golumbeanu
Monica Golumbeanu
JMJörg Johann Möhrle
Jörg Johann Möhrle
MPMelissa A. Penny
Melissa A. Penny
Seasonal malaria chemoprevention (SMC) has proven highly efficacious in reducing malaria incidence. However, the continued success of SMC is threatened by the spread of resistance against one of its main preventive ingredients, Sulfadoxine-Pyrimethamine (SP), operational challenges in delivery, and incomplete adherence to the regimens. Via a simulation study with an individual-based model of malaria dynamics, we provide quantitative evidence to assess long-acting injectables (LAIs) as potential alternatives to SMC. We explored the predicted impact of a range of novel preventive LAIs as a seasonal prevention tool in children aged three months to five years old during late-stage clinical trials and at implementation. LAIs were co-administered with a blood-stage clearing drug once at the beginning of the transmission season. We found the establishment of non-inferiority of LAIs to standard 3 or 4 rounds of SMC with SP-amodiaquine was challenging in clinical trial stages due to high intervention deployment coverage. However, our analysis of implementation settings where the achievable SMC coverage was much lower, show LAIs with fewer visits per season are potential suitable replacements to SMC. Suitability as a replacement with higher impact is possible if the duration of protection of LAIs covered the duration of the transmission season. Furthermore, optimising LAIs coverage and protective efficacy half-life via simulation analysis in settings with an SMC coverage of 60% revealed important trade-offs between protective efficacy decay and deployment coverage. Our analysis additionally highlights that for seasonal deployment for LAIs, it will be necessary to investigate the protective efficacy decay as early as possible during clinical development to ensure a well-informed candidate selection process.

1 July 2017 in Virus Research
Verified
Journal Article
Open access
SRSylvie Rato
Sylvie Rato
MGMonica Golumbeanu
Monica Golumbeanu
Amalio TelentiAmalio Telenti
Amalio Telenti
Angela CiuffiAngela Ciuffi
Angela Ciuffi
Single-cell sequencing (SCS) has emerged as a valuable tool to study cellular heterogeneity in diverse fields, including virology. By studying the viral and cellular genome and/or transcriptome, the dynamics of viral infection can be investigated at single cell level. Most studies have explored the impact of cell-to-cell variation on the viral life cycle from the point of view of the virus, by analyzing viral sequences, and from the point of view of the cell, mainly by analyzing the cellular host transcriptome. In this review, we will focus on recent studies that use single-cell sequencing to explore viral diversity and cell variability in response to viral replication.